Feature Channels: Diabetes

• share
• favorite_border

Researchers from the University of Adelaide could be closer to discovering a better way to use metformin, a common type 2 diabetes medication. Metformin, which has been a cornerstone in diabetes treatment since the 1960s, is typically taken with meals to reduce gastrointestinal side effects but new research is suggesting patients could see improved results if it’s taken before meals.

• share
• favorite_border

Shlomo Melmed, MB, ChB, executive vice president of Medicine and Health Sciences and dean of the Medical Faculty at Cedars-Sinai, has received the Pituitary Society’s top honor for his four decades of pioneering achievements and leadership in the field of endocrinology.

• share
• favorite_border

Mammalian immunity has been shaped from day one by the most successful human pathogens on the planet. Learning how we've evolved together could help scientists understand immune development, treat autoimmune conditions, and make better vaccines.

• share
• favorite_border

Studies from multiple UChicago experts show that while GLP-1RA drugs are extremely effective for weight loss and Type 2 diabetes treatment, there's no one-size-fits-all solution and physicians and patients have to consider issues like cost and side effects.

• share
• favorite_border

A new study by researchers at the Case Western Reserve University School of Medicine reveals that the popular diabetes and weight-loss drugs Wegovy and Ozempic are linked to reduced incidence and recurrence of alcohol abuse or dependence.

• share
• favorite_border

Widespread availability of telemedicine during the pandemic led to more equitable access to endocrinology care for patients with type 2 diabetes and heart disease, according to a study being presented Monday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.

• share
• favorite_border

GLP-1 receptor agonists (GLP-1s) and SGLT-2 inhibitors lower the risk of major cardiovascular events like heart attacks and severe liver complications compared to other diabetes treatments, according to data being presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.

• share
• favorite_border

Metformin is safe to use during pregnancy to manage diabetes, with no long-term adverse effects on the children born and their mothers for at least 11 years after childbirth, according to research presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass. This is the first study to look at longer term effects of metformin use during pregnancy.

• share
• favorite_border

High insulin levels contribute to worse outcomes for Black women compared to white women who have an aggressive form of breast cancer called triple-negative breast cancer, according to a study presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.

• share
• favorite_border

Having medical conditions linked to obesity does not impact the total weight loss achieved with the anti-obesity medication tirzepatide, according to an industry-supported study being presented Saturday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.

• share
• favorite_border

Medications for type 2 diabetes and obesity known as GLP-1 receptor agonists may lower the risk of acute pancreatitis recurrence in people with obesity and those with type 2 diabetes, according to a study presented Saturday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.

• share
• favorite_border

People who have had type 1 diabetes for more than 50 years without kidney complications may still be at substantial risk for heart disease, despite excellent control of blood pressure, cholesterol and blood sugar levels, according to a study presented Saturday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.

• share
• favorite_border

One year after a prediabetes diagnosis, Asians were more likely to develop diabetes mellitus whereas Black patients were more likely to remain in prediabetes range, highlighting racial disparities in diabetes prevention, according to data presented at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.

• share
• favorite_border

Testosterone appears protective against developing type 2 diabetes in men who are overweight or obese and under age 65, but not in men over that age, according to a study presented Saturday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.

• share
• favorite_border

People of color and those who experience social vulnerability are more likely to experience worse glycemic control than their white counterparts, according to research presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.

• share
• favorite_border

Prediabetes increases the risk of dying before age 75, particularly due to heart disease, kidney disease and acute diabetic complications, according to a new study presented Saturday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.

• share
• favorite_border

Health insurance companies often deny coverage for new medications that treat children and teens with obesity and type 2 diabetes, meaning many patients who need treatment are unable to afford it, according to a study presented at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.

• share
• favorite_border

Wounds that are superficial for some can be life-threatening for others. With diabetic wounds, healing can be slow, particularly in the feet, increasing the tissue’s susceptibility to infection. Foot ulcers and other diabetic foot complications have similar mortality rates to some cancers, yet progress toward improved treatments has plateaued.

• share
• favorite_border

Endocrinologists from Cedars-Sinai will present research findings and discuss advances in clinical care throughout ENDO 2024, the Endocrine Society’s annual meeting in Boston, June 1-4.